October 16, 2018 07:05 AM EDT

Taiho antes up an extra $250M for its venture arm as it gets serious about 'global oncology' deals

Amber Tong

Japan’s Taiho Pharma has been scouting the globe for innovations to complement its oncology drug discovery pipeline — and it now appears ready to spend on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Taiho antes up an extra $250M for its venture arm as it gets serious about 'global oncology' deals

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Tai­ho antes up an ex­tra $250M for its ven­ture arm as it gets se­ri­ous about 'glob­al on­col­o­gy' deals

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Taiho antes up an extra $250M for its venture arm as it gets serious about 'global oncology' deals